{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:36:21Z","timestamp":1790361381279,"version":"4.1.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0217433","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T20:04:34Z","timestamp":1560197074000},"page":"e0217433","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":41,"title":["The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6151-4764","authenticated-orcid":true,"given":"Philippe","family":"Gallay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daren","family":"Ure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bobardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udayan","family":"Chatterji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8274-5705","authenticated-orcid":true,"given":"James","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Trepanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.3748\/wjg.v20.i11.2955","article-title":"Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection","volume":"20","author":"CJ Liu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"JJ Ott","year":"2012","journal-title":"Vaccine"},{"key":"ref3","first-page":"289","article-title":"Treatment of liver cancer","volume":"5","author":"CY Liu","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","volume":"479\u2013480","author":"C Seeger","year":"2015","journal-title":"Virology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1136\/gutjnl-2014-308943","article-title":"Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure","volume":"64","author":"MB Zeisel","year":"2015","journal-title":"Gut"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jhep.2014.05.016","article-title":"Bridging basic science and clinical research: the EASL Monothematic Conference on Translational Research in Viral Hepatitis","volume":"61","author":"T Boettler","year":"2014","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/S1473-3099(15)00436-3","article-title":"New therapeutic agents for chronic hepatitis B","volume":"16","author":"M Brahmania","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.gastro.2007.11.036","article-title":"Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach","volume":"134","author":"JM Pawlotsky","year":"2008","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"g3308","DOI":"10.1136\/bmj.g3308","article-title":"Antiviral treatment of hepatitis C","volume":"348","author":"ER Feeney","year":"2014","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrmicro3098","article-title":"The ins and outs of hepatitis C virus entry and assembly","volume":"11","author":"BD Lindenbach","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.bbagen.2014.11.011","article-title":"The role of immunophilins in viral infection","volume":"1850","author":"S Hopkins","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"ref12","doi-asserted-by":"crossref","first-page":"e0134707","DOI":"10.1371\/journal.pone.0134707","article-title":"The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action","volume":"10","author":"PA Gallay","year":"2015","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.virol.2018.06.011","article-title":"Cyclophilins and cyclophilin inhibitors in nidovirus replication","volume":"522","author":"AH de Wilde","year":"2018","journal-title":"Virology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1128\/AAC.00016-14","article-title":"The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance","volume":"58","author":"U Chatterji","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.27960","article-title":"Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection","volume":"62","author":"JM Pawlotsky","year":"2015","journal-title":"Hepatology"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/apt.13342","article-title":"Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-na\u00efve patients with chronic HCV genotype 1 infection (ESSENTIAL II)","volume":"42","author":"S Zeuzem","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.27960","article-title":"Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection","volume":"62","author":"JM Pawlotsky","year":"2015","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/jvh.12360","article-title":"Alisporivir with peginterferon\/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial","volume":"22","author":"M Buti","year":"2015","journal-title":"J Viral Hepat"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.antiviral.2013.03.020","article-title":"Curing a viral infection by targeting the host: the example of cyclophilin inhibitors","volume":"99","author":"K Lin","year":"2013","journal-title":"Antiviral Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/DDDT.S30946","article-title":"Profile of alisporivir and its potential in the treatment of hepatitis C","volume":"7","author":"PA Gallay","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.3390\/v4112558","article-title":"Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection","volume":"4","author":"S Hopkins","year":"2012","journal-title":"Viruses"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.antiviral.2013.09.020","article-title":"Host-targeting agents in the treatment of hepatitis C: a beginning and an end?","volume":"100","author":"JM Baugh","year":"2013","journal-title":"Antiviral Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/372359a0","article-title":"Specific incorporation of cyclophilin A into HIV-1 virions","volume":"372","author":"EK Franke","year":"1994","journal-title":"Nature"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/372363a0","article-title":"Functional association of cyclophilin A with HIV-1 virions","volume":"372","author":"M Thali","year":"1994","journal-title":"Nature"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1128\/AAC.38.8.1763","article-title":"Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog","volume":"38","author":"B Rosenwirth","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1074\/jbc.M809244200","article-title":"Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis\/trans isomerase activity of cyclophilins A and B","volume":"284","author":"X Hanoulle","year":"2009","journal-title":"J Biol Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e13687","DOI":"10.1371\/journal.pone.0013687","article-title":"DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A","volume":"5","author":"L Coelmont","year":"2010","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jhep.2010.01.041","article-title":"HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors","volume":"53","author":"U Chatterji","year":"2010","journal-title":"J Hepatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e9815","DOI":"10.1371\/journal.pone.0009815","article-title":"Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A","volume":"9","author":"F Fernandes","year":"2010","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jhep.2016.11.009","article-title":"Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity","volume":"66","author":"S Shimura","year":"2017","journal-title":"J Hepatol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","article-title":"Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)","volume":"59","author":"K Watashi","year":"2014","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","article-title":"Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor","volume":"60","author":"S Nkongolo","year":"2014","journal-title":"J Hepatol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.gastro.2014.10.004","article-title":"Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production","volume":"148","author":"S Phillips","year":"2015","journal-title":"Gastroenterology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.chembiol.2014.10.023","article-title":"Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection","volume":"22","author":"MJ Hansson","year":"2015","journal-title":"Chem Biol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1128\/AAC.00460-07","article-title":"Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections","volume":"51","author":"GR Painter","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/hep.21445","article-title":"Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice","volume":"45","author":"Y Zheng","year":"2007","journal-title":"Hepatology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1128\/JVI.69.10.6158-6169.1995","article-title":"High-level hepatitis B virus replication in transgenic mice","volume":"69","author":"LG Guidotti","year":"1995","journal-title":"J Virol"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1073\/pnas.93.10.4589","article-title":"Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver","volume":"93","author":"LG Guidotti","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1128\/JVI.02555-09","article-title":"Hepatitis B Virus (HBV) Surface Antigen Interacts with and Promotes Cyclophilin A Secretion: Possible Link to Pathogenesis of HBV Infection","volume":"84","author":"X Tian","year":"2010","journal-title":"J Virol"},{"key":"ref40","unstructured":"Foster R, Ure D, Trepanier D, Sullivan-Bolyai J, Matkovits T, Greytok J, et al. (2017) CRV431: Multiple Therapeutic Actions In Vitro and In Vivo. HEP DART 2017, Kona, Hawaii."},{"key":"ref41","article-title":"The cyclophilin inhibitor CRV431 prevents both HBx-cyclophilin complex formation and HBV replication","author":"R Foster","year":"2017","journal-title":"The International Liver Congress"},{"key":"ref42","article-title":"Parvulin 14 and parvulin 17 bind to HBx and cccDNA and upregulate HBV replication from cccDNA to virion in a HBx-dependent manner","author":"U Saeed","year":"2018","journal-title":"J Virol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5625\/lar.2018.34.3.85","article-title":"Mouse models for hepatitis B virus research","volume":"34","author":"JR Hwang","year":"2018","journal-title":"Lab Anim Res"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.antiviral.2011.01.003","article-title":"Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy","volume":"89","author":"E Lawitz","year":"2011","journal-title":"Antiviral Res"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2012.02.024","article-title":"The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection","volume":"57","author":"S Hopkins","year":"2012","journal-title":"J Hepatol"},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1006\/geno.2000.6295","article-title":"Isolation, characterization and targeted disruption of mouse ppia: cyclophilin A is not essential for mammalian cell viability","volume":"68","author":"J Colgan","year":"2000","journal-title":"Genomics"},{"issue":"6","key":"ref47","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/emboj\/20.6.1300","article-title":"Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells","volume":"20","author":"D Braaten","year":"2001","journal-title":"EMBO J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0217433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T04:01:17Z","timestamp":1608264077000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0217433"}},"subtitle":[],"editor":[{"given":"Haitao","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0217433","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]}}}